On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: The ORION trial

Digestion

Volumn 72, Issue 2-3, 2005, Pages 76-85

  Scholten, T ^a,f   Dekkers, C P M ^d   Schutze K ^e   Korner T ^b   Bohuschke, M ^c   Gatz, G ^c  

^a Allgemeines Krankenhaus Hagen gem GmbH   (Germany)

^b SRH Zentralklinikum Suhl   (Germany)

^c ALTANA PHARMA AG   (Germany)

^d AMPHIA HOSPITAL   (Netherlands)

^e HANUSCH HOSPITAL   (Austria)

^f UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Gastroesophageal reflux disease; GERD; On demand therapy; Pantoprazole; Symptom load

Indexed keywords

ANTACID AGENT; MAGALDRATE; PANTOPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTACIDS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; STATISTICS, NONPARAMETRIC; SULFOXIDES; TREATMENT OUTCOME;

EID: 24944540256     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087661     Document Type: Article

References (27)

1. Loffeld RJ, van der Putten AB: Rising incidence of reflux oesophagitis in patients undergoing upper gastrointestinal endoscopy. Digestion 2003;68:141-144.
2. Shaheen N, Provenzale D: The epidemiology of gastroesophageal reflux disease. Am J Med Sci 2003;326:264-273.
3. Fock KM, Talley N, Hunt R, Fass R, Nandurkar S, Lam SK, Goh KL, Sollano J: Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol 2004;19:357-367.
4. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds JC, Shaw M, Talley NJ on behalf of the Genval Workshop Group. An evidence-based appraisal of reflux disease management - The Genval Workshop Report. Gut 1999;44(suppl 2):S1-S16.
5. Venables TL, Newland RD, Patel AC, Hole J, Copeman MB, Turbitt ML: Maintenance treatment for gastro-esophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol 1997;32:627-632.
6. Hungin AP, Rubin G, O'Flanagan H: Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999;49:463-464.
7. Hungin AP, Rubin GP, O'Flanagan H: Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999;49:451-453.
8. Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, Anker-Hansen O, Stubberod A, Eriksson G, Carlsson R, Junghard O: On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999;13:907-914.
9. Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, Schulz T, Omland TM, Delle M, Junghard O: Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-esophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 month. Aliment Pharmacol Ther 2001;15:347-354.
10. Talley NJ, Venables TL, Green JR, Armstrong D, O'Kaine KP, Giaffer M, Bardhan KD, Carlsson RG, Chen S, Hasselgren GS: Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-esophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002;14:857-863.
11. Kao AW, Sheu BS, Sheu MJ, Chang YM, Huang SF, Chuang CH, Lai YL, Kao YH: On-demand therapy for Los Angeles Grade A and B reflux esophagitis: esomeprazole versus omeprazole. J Formos Med Assoc 2003;102:607-612.
12. Johnsson F, Moum B, Vilien M, Grove O, Simren M, Thoring M: On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol 2002;37:642-647.
13. Cooper AL, Baxter G: Efficacy of lansoprazole on demand therapy in the treatment of non-erosive reflux disease and functional ulcer-like dyspepsia. Gut 2003;52(suppl 6): A137.
14. Bytzer P, Blum A, De Herdt D, Dubois D on behalf of the trial investigators: Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004;20:181-188.
15. Scholten T, Gatz G, Sander P, Bohuschke M: On-demand therapy with pantoprazole 20 mg as effective strategy for long-term treatment in patients with mild GERD. Gut 2002;51(suppl III):A169.
16. Janssen W, Meier E, Gatz G, Pfaffenberger B: On-demand therapy with pantoprazole 20 mg as an effective and safe alternative for the long-term management of patients suffering from mild GERD. Gut 2003;52(suppl VI):A127.
17. Kaspari S, Kupcinskas L, Fischer R, Berghofer P: Effective long-term management of patients suffering from mild GERD with on-demand therapy with pantoprazole 20 mg. Gut 2003;52(suppl VI):A126.
18. Lacevic N, Vukobrat Bijedic Z, Gavrankapetanovic F, Gribajcevic M, Husic Selimovic A, Tanovic H: Efficacy of continued and 'on-demand' regimens of pantoprazole 20 mg in mild gastroesophageal reflux disease. Gut 2003;52(suppl VI):A128.
19. Top PAH, van der Eijk I, Schook CE: Efficacy and safety of pantoprazole used continuously or intermittently in patients with mild gastro-esophageal reflux disease. Gut. 2003;52(suppl VI):A178.
20. Siewert JR, Ottenjann R, Heilmann K, Neiss A, Döpfer H: Therapy and prevention of reflux esophagitis. Results of a multicenter study with cimetidine. I. Epidemiology and results of acute therapy. Z Gastroenterol 1986;24:381-395.
21. Moretzsohn LD, Brito EM, Reis MS, Coelho LG, Castro L de P: Assessment of effectiveness of different dosage regimens of pantoprazole in controlling symptoms and healing esophageal lesions of patients with mild erosive esophagitis. Arq Gastroenterol 2002;39:123-125.
22. Van Zyl JH, de K Grundling H, van Rensburg CJ, Retief FJ, O'Keefe SJ, Theron I, Fischer R, Bethke T: Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-esophagitis: a randomized, double-blind, parallel, and multicentre study. Eur J Gastroenterol Hepatol 2000;12:197-202.
23. Dettmer A, Vogt R, Sielaff F, Luehmann R, Schneider A, Fischer R: Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux esophagitis. Aliment Pharmacol Ther 1998;12:865-872.
24. Bardhan KD: Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98(suppl):S40-S48.
25. Bytzer P: On-demand therapy for gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 2001;13(suppl):S19-S22.
26. Inadomi JM: On-demand and intermittent therapy for gastroesophageal reflux disease. Pharmacoeconomics 2002;20:565-576.
27. Quigley EMM: Non-erosive reflux disease: part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia or both? Eur J Gastroenterol Hepatol 2001;13(suppl 1):S13-S18.